DANAHER CORP /DE/

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

ReportTypeUpdatedReadActions

Danaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.NYSEJun 5, 2026Research reportRead Slides

Danaher: life-science quality has to show up in bioprocess recovery and cash conversionDanaher reported 2025 revenue of $24.57 billion and Q1 2026 revenue of $5.95 billion. The thesis depends on bioprocess recovery, diagnostics demand, operating leverage, acquisitions and cash conversion.NYSEMay 20, 2026Research reportRead Slides

Danaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?

Financials and workspace tools are for paid members.

Recent Reports